CTRI/2022/03/041108招募中未知
COX-2 inhibitors in management of patients with oral submucous fibrosis: A Prospective Randomized Open Blinded End-point (PROBE) Study
Applied for intramural grant RIMS Ranchi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Consecutive patients with clinically suspected OSMF will be considered for the study.
- •2. Patients with current or previous use of any form of smokeless tobacco and/or areca nut (any duration and frequency)
- •3. Patients having late-stage OSMF designated as Grade III and IV by the grading system proposed by Kerr et al.
- •4. Patients willing to quit the habit of smokeless tobacco and/or areca nut.
- •5. Patients willing to accept regular follow-up protocol
- •6. Histopathological confirmation of OSMF by incisional biopsy
排除标准
- •1.Patients having early-stage OSMF designated as Grade I and II by the grading system proposed by Kerr et al.
- •2.Patients with known allergy or contra-indication to COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides.
- •3.Patients having diagnosis or treatment of esophageal, gastric, pyloric channel, or duodenal ulceration within past 30 days, prior or active pancreatic disease or inflammatory bowel disease or Hemophilia or a history of bleeding disorders or Gout or a history of gout
- •4.Patients already undergoing treatment for OSMF.
- •5.Pregnant and lactating females.
- •6.Patients having concomitant pericoronitis or any other dental condition leading to trismus.
研究者
相似试验
进行中（未招募）
不适用
COX-2-hämmare och kemoterapi vid avancerad icke småcellig lungcancer. En prospektiv randomiserad dubbel-blind studie.Key elements: CYclooxygenase-2 inhibitor, Chemotherapy, LUng cancer, Survival (CYCLUS-studien) - CYCLUS-studieHistologiskt eller cytologiskt veriferad icke småcellig lungcancer, stadium IIIB-IV, som inte kan behandlas med operation eller kurativt syftande strålbehandling. WHO performance status 0-2.EUCTR2005-000717-35-SEungmedicinska kliniken
已完成
不适用
Efficacy of the treatment with a COX-2 specific inhibitor celecoxib in osteoarthritic patientsAdvanced osteoarthritisMusculoskeletal DiseasesOsteoarthritis (OA)ISRCTN55717501Hospital de Tortosa Virgen de la Cinta (Spain)30
进行中（未招募）
1 期
Cyclooxygenase inhibitor therapy in patients with oesophageal adenocarcinoma: A pilot study - CITAEUCTR2005-000988-26-GBPortsmouth Hospitals NHS Trust32
已完成
不适用
Evaluation of selective COX-2 inhibitor for the protection of intestinal mucosal damage in comparison to NSAID in patients with rheumatoid arthritis (Investigation by capsule endoscopy and measurement of biomarkers for rheumatoid arthritis)JPRN-UMIN000002554Osaka University30
进行中（未招募）
不适用
Clinical effectiveness and effect on COX-2 expression of the sequential treatment of actinic keratoses (AK) with photodynamic therapy (PDT) and diclofenac 3% gel: a phase IV clinical trialActinic keratosisMedDRA version: 15.1Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2013-000110-37-ESFundacion para la investigación biomédica del hospital Ramón y Cajal de Madrid